Search results
Results from the WOW.Com Content Network
ICD-10 is the 10th revision of the International Classification of Diseases (ICD), a medical classification list by the World Health Organization (WHO). It contains codes for diseases, signs and symptoms, abnormal findings, complaints, social circumstances, and external causes of injury or diseases. [1]
ICD-10-PCS: C8191ZZ: LOINC: 39670-5: Dacryoscintigraphy (DSG), also known as lacrimal scintigraphy, is a nuclear medicine technique for imaging the lacrimal apparatus.
Medical imaging is the technique and process of imaging the interior of a body for clinical analysis and medical intervention, as well as visual representation of the function of some organs or tissues . Medical imaging seeks to reveal internal structures hidden by the skin and bones, as well as to diagnose and treat disease.
The natural distribution of causation for primary hyperparathyroidism is roughly 85% solitary adenomas, 10-15% diffuse hyperplasia, and 1% cancer. Imaging is not as reliable in patients with multiglandular parathyroid disease. In addition, size limitation of the abnormal gland can limit the detection by radionuclide scanning.
ICD-9-CM: Volumes 1 and 2 only. Volume 3 contains Procedure codes: ICD-10: The international standard since about 1998 ICPC-2: Also includes reasons for encounter (RFE), procedure codes and process of care International Classification of Sleep Disorders: NANDA: Diagnostic and Statistical Manual of Mental Disorders: Primarily psychiatric disorders
The ICD-10 Procedure Coding System (ICD-10-PCS) is a US system of medical classification used for procedural coding.The Centers for Medicare and Medicaid Services, the agency responsible for maintaining the inpatient procedure code set in the U.S., contracted with 3M Health Information Systems in 1995 to design and then develop a procedure classification system to replace Volume 3 of ICD-9-CM.
The ICD-10 Clinical Modification (ICD-10-CM) is a set of diagnosis codes used in the United States of America. [1] It was developed by a component of the U.S. Department of Health and Human services, [ 2 ] as an adaption of the ICD-10 with authorization from the World Health Organization .
The dose is typically 0.15–0.37 MBq (4–10 μCi) of 131 I iodide, or 3.7–7.4 MBq (100–200 μCi) of 123 I iodide. [2] The RAIU test is a reliable measurement when using a dedicated probe with a reproducibility of 1 percent and a 95%-least-significant-change of 3 percent.